TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23646099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LD-¹³C with randomized CD doses (0, 25, 50, 100 and 200 mg)
Study: 23646099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LD-¹³C with increasing CD doses
Study: 23646099
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg LD-¹³C
Study: 19356374
Drug: Oxymetholone 50
Normalized name: oxymetholone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymetholone 50 mg orally twice daily for 24 weeks
Study: 19356374
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 24 weeks
Study: 18080043
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) treatment (400 microT), twice-daily 40 min treatments over seven days
Study: 16805716
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (high doses)
Study: 16805716
Drug: Less intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intensive statin therapy
Study: 15242434
Drug: Double injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double injection of 15 ml of 0.75% ropivacaine to each sciatic nerve component (total 30 ml)
Study: 15242434
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 30 ml of 0.75% ropivacaine to the sciatic nerve
Study: 10866909
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection
Study: 8620641
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (primary repair plus early controlled mobilization)
Study: 8620641
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment (early controlled mobilization alone)
Study: 12602423
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (CBT)
Study: 26594944
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (CBT) and Interpersonal psychotherapy (IPT)
Study: 19577636
Drug: Subvirion avian
Normalized name: Asian ginseng extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion avian influenza A/H5N1 vaccine with aluminum hydroxide (AlOH)
Study: 19577636
Drug: Subvirion avian
Normalized name: Asian ginseng extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion avian influenza A/H5N1 vaccine without aluminum hydroxide (AlOH)
Study: 19577636
Drug: Subvirion avian
Normalized name: Asian ginseng extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion avian influenza A/H5N1 vaccine (all doses)
Study: 19577636
Drug: Subvirion avian
Normalized name: Asian ginseng extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion avian influenza A/H5N1 vaccine (45microg HA)
Study: 19577636
Drug: Subvirion avian
Normalized name: Asian ginseng extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subvirion avian influenza A/H5N1 vaccine (45microg HA with AlOH)
Study: 15204280
Drug: Upward loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upward loading with different load magnitudes (250, 750, and 1250 g) during five- and three-digit grasps.
Study: 15204280
Drug: Downward loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Downward loading with different load magnitudes (250, 750, and 1250 g) during five- and three-digit grasps.
Study: 11579363
Drug: Carvedilol monotherapy
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol monotherapy
Study: 11579363
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Captopril + Carvedilol)
Study: 9795022
Drug: Rectal suppository
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppository
Study: 7986489
Drug: D-cycloserine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (25 to 500 mg daily, dose escalation phase)
Study: 2929903
Drug: Lignocaine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 1.5 mg/kg
Study: 26905703
Drug: Lignocaine 2
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 2 mg/kg
Study: 27943397
Drug: Thiopurine treatment
Normalized name: thiotaurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopurine treatment with 6-MMP concentrations measured at T1 (1 week after treatment initiation)
Study: 24089534
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NT-proBNP and hs-cTnT
Study: 21122848
Drug: 600‐μg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600‐μg oral misoprostol
Study: 8588792
Drug: dimenhydrinate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: dimenhydrinate (100 mg)
Study: 15468399
Drug: Topical negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical negative pressure dressing
Study: 11854606
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 500 mg b.i.d. for a mean of 12.5 weeks
Study: 10510161
Drug: Digoxin alone
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin alone (0.5 mg)
Study: 10510161
Drug: Digoxin with
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin with macrogol 4000 (20 g day-1 for 8 days)
Study: 7737960
Drug: Adinazolam-SR 60
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam-SR 60 mg/day
Study: 7737960
Drug: Adinazolam-SR 90
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam-SR 90 mg/day
Study: 7737960
Drug: Adinazolam-SR 30
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam-SR 30 mg/day
Study: 2439814
Drug: bopindolol 1
Normalized name: bopindolol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bopindolol 1 mg
Study: 30853250
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (50 mg/kg once daily) at home
Study: 30853250
Drug: Intravenous flucloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flucloxacillin (50 mg/kg every 6 h) in hospital
Study: 28395998
Drug: Collagenase Clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase Clostridium histolyticum (CCH) intralesional injection (0.58 mg/injection, up to eight injections)
Study: 28395998
Drug: CCH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCH treatment of male partners
Study: 24946799
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy (30 sessions)
Study: 24946799
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy (30 sessions)
Study: 23002124
Drug: PEG‐IFN (peginterferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN (peginterferon alfa‐2b), 6 μg/kg per week for eight doses, followed by 3 μg/kg per week for up to 252 weeks
Study: 19735181
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g n-3 PUFAs
Study: 19735181
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g n-3 PUFAs
Study: 9007484
Drug: Tetanus-PRP conjugate
Normalized name: HEMOPHILUS B CONJUGATE(TETANUS TOXOID CONJUGATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus-PRP conjugate vaccine
Study: 8393606
Drug: 10(4) p.f.u.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(4) p.f.u. dose of rhesus rotavirus serotype 3
Study: 8393606
Drug: 10(5) p.f.u.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(5) p.f.u. dose of rhesus rotavirus serotype 3
Study: 8393606
Drug: 10(4) p.f.u.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(4) p.f.u. dose of tetravalent rotavirus vaccine
Study: 8393606
Drug: 10(5) p.f.u.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10(5) p.f.u. dose of tetravalent rotavirus vaccine
Study: 8393606
Drug: Grouped vaccines
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grouped vaccines at 10(5) p.f.u. (single serotype and tetravalent)
Study: 3578925
Drug: Intranasal IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal IgE pentapeptide 0.5%
Study: 27619403
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg omega-3 fatty acids from flaxseed oil containing 400 mg α-Linolenic acid plus 400 IU vitamin E supplements (n = 34)
Study: 27619403
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg omega-3 fatty acids and vitamin E co-supplementation
Study: 17264186
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (1 mg/m2.d)
Study: 11325685
Drug: Intravenous L-carnitine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine, 20 mg/kg
Study: 11325685
Drug: Intravenous L-carnitine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine, 10 mg/kg
Study: 11325685
Drug: Intravenous L-carnitine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine, 40 mg/kg
Study: 2122016
Drug: Intravenous L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous L-carnitine
Study: 9621293
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment applied at the cannula site after catheter placement and at the end of each dialysis session
Study: 2363109
Drug: Lidocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (20 mg/ml) with epinephrine (12.5 micrograms/ml)
Study: 2363109
Drug: Prilocaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine (30 mg/ml) with felypressin (0.54 microgram/ml)
Study: 2363109
Drug: Mepivacaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine (30 mg/ml)
Study: 21508826
Drug: S-ketamine 20
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine 20 mg/70 kg/h with rifampicin (600 mg once daily for 5 days)
Study: 21508826
Drug: S-ketamine 40
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine 40 mg/70 kg/h with rifampicin (600 mg once daily for 5 days)
Study: 15593207
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous cyclophosphamide (IV CYC) regimen (6 pulses of 500 mg given at intervals of 2 weeks) followed by azathioprine (AZA)
Study: 15593207
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous cyclophosphamide (IV CYC) regimen (6 monthly pulses and 2 quarterly pulses with escalating doses) followed by azathioprine (AZA)
Study: 15593207
Drug: Early response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early response to therapy (defined as a decrease in serum creatinine level and proteinuria <1 g/24 hours)
Study: 8333773
Drug: Intermittent growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent growth hormone treatment (three weeks of every four)
Study: 8333773
Drug: Continuous growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous growth hormone treatment (daily injection)
Study: 26225500
Drug: QLB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLB with 0.125% bupivacaine 0.2 ml kg⁻¹ (Group 1)
Study: 26225500
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (QLB with 0.9% Normal saline 0.2 ml kg⁻¹)
Study: 24190233
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (EPA 1245 mg/day, DHA 540 mg/day)
Study: 18706028
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN, 5 mg/day)
Study: 8576660
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA (Patient-Controlled Analgesia)
Study: 8576671
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method (Intramuscular q.i.d. injection and p.r.n. injection)
Study: 2354091
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of plain 0.5% bupivacaine injected at L3-4
Study: 2354091
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of plain 0.5% bupivacaine injected at L4-5
Study: 29171020
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg on day 1 and 75 mg on day 2)
Study: 29171020
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg on day 1 and 10 mg on day 2)
Study: 20134306
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (triamcinolone acetonide)
Study: 22721455
Drug: NSAID injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID injection (diclofenac sodium)
Study: 19672733
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - oral 0.625 mg conjugated estrogen + 2.5 mg medroxyprogesterone acetate/day for 3 and 6 months
Study: 17377770
Drug: Intravenous fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fish oil fat emulsion (0.5 g/kg 10% emulsion, Omegaven) administered twice, 48 and 24 hours before investigation.
Study: 14977388
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg daily
Study: 16276692
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 400 microg twice daily
Study: 14618035
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (amiodarone, propafenone, flecainide, sotalol)
Study: 16698176
Drug: Propiverine 15
Normalized name: propiverine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 15 mg t.i.d.
Study: 7606516
Drug: Nedocromil sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil sodium, 4 mg aerosol 30 min before challenge
Study: 2206227
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug treatment (azathioprine, cyclosporin, methylprednisolone)
Study: 2206227
Drug: CyA monotherapy
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA monotherapy (group B)
Study: 2206227
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug treatment
Study: 2206227
Drug: Aza and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aza and MP, CyA monotherapy, CyA and MP (controls)
Study: 400933
Drug: Cefoxitin (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2.0 g intramuscularly with 1.0 g of oral probenecid)
Study: 400933
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G (4.8 x 10(6) units intramuscularly with 1.0 g of oral probenecid)
Study: 15200541
Drug: Bupivacaine irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine irrigation through the axillary wound drain 4-hourly for 24 h postoperatively
Study: 12047399
Drug: glyburide/metformin 1.25/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide/metformin 1.25/250 mg
Study: 12047399
Drug: glyburide/metformin 2.5/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide/metformin 2.5/500 mg
Study: 12047399
Drug: glyburide/metformin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: glyburide/metformin (both doses)
Study: 2059756
Drug: Methotrexate (MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (MTX 10 mg/m2) given on days 1, 3, and 6, and daily cyclosporine (CSP) on days -1 through 180
Study: 2059756
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of MTX and daily CSP
Study: 6841304
Drug: Acyclovir, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 10 and 15 mg/kg 8 hourly, given as an iv bolus or iv infusion over 1 h for up to 7 days
Study: 6841304
Drug: Acyclovir, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 10 and 15 mg/kg 8 hourly, given as an iv bolus
Study: 6841304
Drug: Acyclovir, high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, high dosage by iv bolus mode of administration
Study: 6841304
Drug: Acyclovir, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 15 mg/kg 8‐hourly
Study: 30058646
Drug: Oral CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral CoQ10 supplementation
Study: 26177791
Drug: Alendronate (ALN)
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate (ALN) 70 mg weekly for 48 weeks
Study: 26177791
Drug: Baseline 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline 25(OH)D < 32 ng/mL
Study: 20150883
Drug: 1 Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Hz real-rTMS of the SI cortex for 30 minutes daily for 5 days
Study: 16188715
Drug: Psychotherapy (eight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (eight sessions of cognitive behavioral therapy) plus pharmacotherapy (citalopram)
Study: 12885836
Drug: Standard timing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard timing chemotherapy (DCTER: dexamethasone, cytarabine arabinoside, 6‐thioguanine, etoposide, daunorubicin)
Study: 12885836
Drug: Standard timing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard timing chemotherapy (DCTER)
Study: 8458774
Drug: Naloxone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (3 mg intravenous infusion)
Study: 2429117
Drug: Clonidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (200 micrograms as a single dose)
Study: 2429117
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of clonidine (200 micrograms twice a day for 3 weeks)
Study: 2429117
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of clonidine (400 micrograms twice a day for 6 weeks)
Study: 22751847
Drug: Fingolimod, 0.5
Normalized name: Fingolimod, 0.5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod, 0.5 mg
Study: 30439315
Drug: Comfort analgesic
Normalized name: Comfort Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comfort analgesic sedative scheme with immediate analgesia and sedation score, CPOT 0-1 and RASS -1-0.
Study: 30439315
Drug: Daily analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily analgesic and sedation regimen with CPOT 0-3 and RASS maintained at -3 to -4.
Study: 19945740
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of chemotherapy
Study: 19945740
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of chemotherapy
Study: 7200653
Drug: Topical instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical instillation of adriamycin
Study: 27333382
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (15 mg/kg/day for 12 months)
Study: 17720098
Drug: Gamma tocopherol
Normalized name: Gamma tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma tocopherol (308 mg) and DHA (800 mg)
Study: 15161110
Drug: Protease supplementation
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease supplementation (two tablets containing 325 mg pancreatic enzymes, 75 mg trypsin, 50 mg papain, 50 mg bromelain, 10 mg amylase, 10 mg lipase, 10 mg lysozyme, 2 mg chymotrypsin) four times a day for 4 days starting 1 day before exercise
Study: 11800415
Drug: Trimetazidine 20
Normalized name: trimetazidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 20 mg orally every 8 hours during hospitalization
Study: 2610721
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 200 mg naftidrofuryl
Study: 30647436
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg phospholipid curcumin, one capsule per day for 8 weeks
Study: 29061728
Drug: Coupler implantation
Normalized name: Complera
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Coupler implantation and continuing previous pharmacotherapy
Study: 29061728
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment alone
Study: 26867335
Drug: Dual cycle
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual cycle and dual channel treatment (Group B)
Study: 26867335
Drug: Conventional single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional single cycle treatment (Group A)
Study: 21931204
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg, one tablet every 6 hours for three days
Study: 12801493
Drug: Auricular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular therapy using magnetic pearls
Study: 10826459
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg twice daily for 5 days followed by 400 mg twice daily for 5 days